Salt Lake City, UT – According to filings with the U.S. Securities and Exchange Commission, Teiko.bio is raising $15,290,024.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Ramji Srinivasan played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Teiko.bio
Teiko.bio equips scientific and clinical teams with actionable intelligence at a cellular level. Pairing cutting-edge mass cytometry with a high-dimensional machine learning model, teiko.bio unlocks more information about individual immune characteristics to drive clinical insights. Teiko.bio was founded with a simple purpose: use immune insights to help deliver life changing therapies to those who need them most. Today, Teiko delivers on its mission by supporting therapy development and informing clinical decision making. Mass Cytometry is a mass spectrometry method used to determine specific properties of cells. It is an advanced cytometry method that builds upon the established science of flow cytometry while eliminating many of the common challenges associated with the technique. Armed with in-depth immune information, researchers can make informed decisions around patient response and drive new pathway discoveries.

To learn more about Teiko.bio, visit http://teiko.bio/

Contact:
Ramji Srinivasan, Chief Executive Officer
415-729-4717
ramji@teiko.bio
https://www.linkedin.com/in/ramjisrinivasan/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved